Core-Shell Nanomedicine for Targeting Multiple Targets in Cancer
The Amrita Center for Nanosciences and Molecular Medicine has developed a novel core-shellnanomedicine that can simultaneously target two critical cancer mechanisms in drug resistant blood cancer. Chronic myeloid leukemia (CML) is a type of blood cancer caused by a protein known as BCR-ABL, a protein not found in healthy individuals. Existing drugs, such as Imatinib and Dasatinib, can prevent the development of the BCR-ABL protein and kill leukemic cells. However, patients become resistant to these drugs after some time, making the disease difficult to treat. In addition to the BCR-ABL protein, a protein called STAT5 is also present in patients that have developed resistance to drugs. No drug, however, has been able to simultaneously prevent the activities of BCR-ABL and STAT5 together, but researchers at the Amrita Center for Nanosciences and Molecular Medicine have developed nanomedicines that show efficacy to both BCR-ABL and STAT5. The nanomedicines were rationally designed with the help of computational tools and were later developed into a core-shell architecture using naturally available proteins. The nano-core contained the drug that targets the BCR-ABL protein and the nano-shell contained the drug that targets STAT5. The core-shell nanoparticles showed significant toxicity to the CML cells.